Aricept Complexed with Acetylcholinesterase
From Proteopedia
(Difference between revisions)
Line 20: | Line 20: | ||
==Additional Resources== | ==Additional Resources== | ||
For additional information, see: [[Alzheimer's Disease]]<br /> | For additional information, see: [[Alzheimer's Disease]]<br /> | ||
- | + | ||
<br /> | <br /> | ||
</StructureSection> | </StructureSection> | ||
Line 41: | Line 41: | ||
[[vi:Aricept_Complexed_with_Acetylcholinesterase (Vietnamese)]] | [[vi:Aricept_Complexed_with_Acetylcholinesterase (Vietnamese)]] | ||
[[tr:Aricept_Complexed_with_Acetylcholinesterase (Turkish)]] | [[tr:Aricept_Complexed_with_Acetylcholinesterase (Turkish)]] | ||
+ | [[hi:Aricept Complexed with_Acetylcholinesterase (Hindi)]]<br /> | ||
[[Category: Acetylcholinesterase]] | [[Category: Acetylcholinesterase]] |
Revision as of 09:11, 10 January 2018
|
Reference
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307. PMID:10368299
Proteopedia Page Contributors and Editors (what is this?)
Eran Hodis, Joel L. Sussman, Jaime Prilusky, Alexander Berchansky, OCA, Michal Harel, David Canner, Wayne Decatur, Pham Ngoc Phuong, Angel Herraez, Lucie Kolarova